{
    "id": 20481,
    "fullName": "ATR positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ATR positive indicates the presence of ATR gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 545,
        "geneSymbol": "ATR",
        "terms": [
            "ATR",
            "FCTCS",
            "FRP1",
            "MEC1",
            "SCKL",
            "SCKL1"
        ]
    },
    "variant": "positive",
    "createDate": "03/30/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5517,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-970 sensitized patient-derived lung cancer cells to cisplatin in culture and in PDX models (PMID: 25010037).",
            "molecularProfile": {
                "id": 20962,
                "profileName": "ATR positive"
            },
            "therapy": {
                "id": 3109,
                "therapyName": "Cisplatin + VX-970",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5082,
                    "pubMedId": 25010037,
                    "title": "Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25010037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2497,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human breast cancer cell lines demonstrated sensitivity to VE-821 in culture, resulting in decreased cell survival (PMID: 25468710).",
            "molecularProfile": {
                "id": 20962,
                "profileName": "ATR positive"
            },
            "therapy": {
                "id": 2877,
                "therapyName": "VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3170,
                    "pubMedId": 25468710,
                    "title": "Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25468710"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20962,
            "profileName": "ATR positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27648,
            "profileName": "ATM dec exp ATR pos HDAC1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}